How can we better model inflammation to improve immune-targeting therapies?
In this webinar, learn how human-relevant 3D in vitro disease models help capture key inflammatory mechanisms and support better drug ranking and selection.
🎥Watch here: shorturl.at/UX8LY
Read our publication "Modeling hepatocellular carcinoma and its microenvironment on a chip" where we developed a vascularized, patient-derived HCC-on-a-chip model to study tumor–microenvironment interactions and screen 28 treatment conditions in HCC.
doi.org/10.1038/s414...
GI toxicity is a major hurdle in drug development.
Our latest case study shows how the Perfused OrganoReady® Colon Organoid enables human-relevant GI safety assessment with real-time barrier, metabolic, and transport readouts.
Read the full case study: www.mimetas.com/case-studies...
Learn how our Uniflow Technology delivers continuous unidirectional, physiological flow without external pumps, supporting robust vascular models for drug testing and immune–vascular studies.
⬇️ Download the poster: www.mimetas.com/resources/pe...
Behind the scenes 🎬
Last Thursday, the #NewDutch team visited MIMETAS to film. Our VP of Biology Henriëtte Lanz was interviewed, sharing how MIMETAS is advancing human-relevant research through our Organ-on-a-Chip technology.
#Leidenstadvanontdekkingen #Leidencityofscience
New publication from MIMETAS 🧠 A scalable 3D human BBB model under gravity-driven, unidirectional flow. Built with self-assembling triculture microvasculature, it combines physiological relevance with higher-throughput capability for BBB research and drug discovery.
🔗 www.mimetas.com/news/mimetas...
Customer spotlight at #SLAS2026
Mayu Shibuta from Astellas Pharma showcased an Automated Organ-on-a-Chip Platform for Scalable Drug Testing using the OrganoPlate® platform!
Automation + Organ-on-a-Chip = scalable, reproducible, human-relevant drug testing.
#OrganOnAChip #Automation
Poster alert for #SLAS2026! Our collaborators at Tecan are presenting functional intestinal ADME/Tox testing using the MIMETAS OrganoReady® Colon Organoid Model + Tecan Spark Cyto.
📍Boston | Feb 11, 12–1 PM | Poster 1309-E
www.mimetas.com/organoready-...
#Organoids #ADMETox
We’re proud to share that MIMETAS is a founding member of IAMPS, the world’s first industry alliance dedicated to advancing microphysiological systems (MPS).
With 8 other European innovators, IAMPS will accelerate regulatory acceptance, standardization & adoption of #NAMs. shorturl.at/dLRcF
Day 2 at #WORD+ 2026!
Our team is ready to go at Booth #6 to discuss how MIMETAS' Organ-on-a-Chip models can not just support but accelerate your research projects.
Also, don't forget to check out our poster on Predicting Gastrointestinal Toxicity!
Great start at #WORD+2026! Today, Pleun Hombrink (Director of Bioproduction & Screening at MIMETAS) shared how integrating colon organoids with MPS can enable more predictive, scalable drug discovery.
Stop by booth #6 to meet the team!
#NAMsInAction #Organoids #OrganOnAChip #MPS
We’re hiring a Junior Scientist at MIMETAS! 🧬
Join our Model Development team in Leiden and work hands-on with cutting-edge organ-on-a-chip technology to shape the future of drug discovery.
📍 Leiden, NL
👉 Apply here: mimetas.easycruit.com/vacancy/3585...
#Hiring #LifeSciencesJobs #Biotech
Great discussions at Designing the Future Through Patient-Based Drug Development by Ombion.
Our CEO Jos Joore presented on Enabling Human Biology in Regulatory Science, showing how fit-for-purpose #NAMs can strengthen regulatory decision-making and advance drug development.
💡 Publication spotlight:
Swiss Institute of Allergy and Asthma Research researchers used the OrganoPlate® platform to develop Caco-2 and colon organoid models to study how food emulsifiers affect gut epithelial barrier integrity and inflammatory signaling.
🔗 onlinelibrary.wiley.com/doi/10.1111/...
🧠 Did you see the human BBB image we shared recently? In this webinar, learn how we develop a perfused human BBB model for disease modeling and DMPK studies, including stroke, neuroinflammation, toxicity testing, and drug transport: register.gotowebinar.com/register/189...
🧠 A fluorescence image of a human BBB model combining HBMECs, astrocytes, and pericytes. Claudin-5 (green), GFAP (red), and Hoechst (blue) reveal organized BBB architecture supporting studies of BBB function and drug transport. Discover the model: shorturl.at/APOzu
New drug modalities bring new safety challenges.
Watch our on-demand webinar to learn how human 3D in vitro models & organ-on-a-chip improve toxicity prediction. shorturl.at/ONaf3
#DrugDiscovery #Toxicology #OrganOnAChip
Barrier dysfunction is key in gut disease and drug safety. Our study in MDPI Toxins shows a scalable, multi-parameter way to assess gut barrier integrity in MIMETAS' OrganoReady® gut models, supporting compound safety assessment and drug development.
🔗 www.mdpi.com/2072-6651/17...
Merry Christmas🎄✨
Thanks for being part of the MIMETAS journey in 2025 –good science, great collaborations, and yes… that website you may have already clicked through 😉
See you in the New Year!
The U.S. Senate has passed the FDA Modernization Act 3.0, moving FDA regulations closer to current nonclinical practice. The bill updates outdated “animal” testing language and supports broader use of human-relevant methods in drug development.
buddycarter.house.gov/news/documen...
Attivare Therapeutics (Wyss Institute spin-out) has joined Oncode Accelerator with a new Demonstrator Project, which MIMETAS is a key partner in.
Together with Amsterdam UMC we’re working to improve translational oncology for hard-to-treat cancers. www.oncodeaccelerator.nl/news/wyss-in...
✨ Last Friday, MIMETAS wrapped up the year with our Christmas Party!
From dinner ➝ team-voted awards (Best Dressed, OrganoPlate Whisperer, PowerPoint Wizard, Energy Booster) ➝ dancing 💃🕺
We’re grateful for the people and energy that make MIMETAS what it is.
#TeamCulture
Proud to be featured by the Netherlands platform!
At MIMETAS, we’re working to transform drug development with human-relevant in vitro models that better predict clinical outcomes – accelerating safer, more effective medicines.
🔗 Read the article: nlplatform.com/articles/-MI...
Model choice matters in liver disease research. Our webinar shows how MIMETAS 3D in-vitro liver models are used for fibrosis, steatosis & metabolic assays, incl. automated anti-fibrotic screening. Watch: shorturl.at/mpQPc
#LiverModel #Fibrosis #DrugDiscovery
This paper shows a microvascularized liver model with hepatocytes, stellate cells, and a self-organized perfusable endothelial plexus - native-like structure and HTS-ready robustness (excellent Z’). Big step for #MASH & anti-fibrotic screening research. Read here: shorturl.at/gOskI
#LiverOnAChip
Looking for a physiologically relevant gut model in vitro? MIMETAS’ scalable 3D human gut models recreate key intestinal features, combining epithelium + perfused vasculature, stroma & immune components for more predictive barrier, ADME, toxicity & inflammation studies. shorturl.at/87E8x
❓How can we better model the human blood-brain barrier for CNS disease and drug development? From tight barrier formation to applications in stroke, neuroinflammation, toxicity testing, small-molecule transport, and antibody transcytosis - explore our 3D BBB-on-chip models: tinyurl.com/54wm4d4t
🚀 It’s here! We’re excited to unveil a fully redesigned website for MIMETAS. Built around how you explore science - from models and technology to screening, analysis, and ready-to-use tissues - all in one intuitive place. See for yourself: mimetas.com #OrganOnAChip #3DTissueModels #DrugDiscovery
🎓 Congrats to Dr. Murillo Bernardi on his successful PhD defense! His thesis, “From Chick to Chip - Novel models to bridge in vitro and in vivo kidney research” presents years of work on advancing predictive kidney models at UMC Utrecht and MIMETAS.
#PhDDefense #MIMETAS
In this app note, learn how MIMETAS’ OrganoReady® Blood Vessel models enable high-throughput, human-relevant toxicity screening in 3D microfluidic blood vessel systems. Ultimately, this supports the development of safer therapeutics and better treatment strategies.
🔗 shorturl.at/gtn5M
